AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy

Nguyen, Hai Truong; Okuku, Fred; Ssewankambo, Fred; Magaret, AS; Johnston, Christine; Wald, Anna; Kambugu, Andrew; Corey, Lawrence; Orem, Jackson; Casper, Corey

doi:10.1186/1750-9378-4-s2-o5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To minimize this problem, we modeled the cumulative number of chemotherapy doses within the past 105 days as a time-varying covariate. One hundred five days was chosen based on previous work at UCI38 and as the minimum approximate time needed to complete at least six 2–3 week cycles of chemotherapy, and treatment-free periods between them. This variable was kept in the multivariate model regardless of the significance level.…”

Section: Methodsmentioning

confidence: 99%

Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment

Bateganya¹,

Stanaway²,

Brentlinger³

et al. 2011

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Objective We examined factors associated with survival among patients with newly diagnosed non-Hodgkin's lymphoma (NHL) in Uganda. Methods Information was abstracted from medical records for all NHL patients >13 years of age at the Uganda Cancer Institute between January 2004 and August 2008. Cox proportional hazard models were used to identify predictors of NHL survival. Results 160 patients with NHL were identified; 51 (31.9%) were known to be human immunodeficiency virus (HIV) positive. Overall, 154 patients had records sufficient for further analysis. The median person-time observed was 104 days (interquartile range (IQR) 26–222). Median survival after presentation among those whose mortality status was confirmed was 61 days (IQR 25–203). HIV-positive patients receiving antiretroviral therapy (ART) had survival rates approximating those of HIV-negative persons, but the adjusted hazard of death was significantly elevated among HIV-positive patients not receiving ART (aHR 8.99, p < 0.001) compared to HIV-negative patients. Both B-symptoms (HR 2.08, p = 0.05) and female gender (HR 1.72, p = 0.05) were associated with higher mortality. Conclusions In Uganda, overall survival of NHL patients is poor, and predictors of survival differed from those described in resource-rich regions. HIV is a common co-morbidity to NHL, and its lack of treatment was among the strongest predictors of mortality. Strategies are needed for optimal management of HIV-infected individuals with cancer in resource-limited settings.

show abstract

Section: Methodsmentioning

confidence: 99%

Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment

Bateganya¹,

Stanaway²,

Brentlinger³

et al. 2011

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy

Abstract: Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical researc h in our lifetime."

Cited by 1 publication

References 0 publications

Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment

Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment

Contact Info

Product

Resources

About